These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 38022667)
21. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. André T; Cohen R; Salem ME Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834 [TBL] [Abstract][Full Text] [Related]
22. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146 [TBL] [Abstract][Full Text] [Related]
23. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. Morse MA; Hochster H; Benson A Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813 [TBL] [Abstract][Full Text] [Related]
25. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. Quiroga D; Lyerly HK; Morse MA Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067 [TBL] [Abstract][Full Text] [Related]
26. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era? Matteucci L; Bittoni A; Gallo G; Ridolfi L; Passardi A Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958363 [TBL] [Abstract][Full Text] [Related]
27. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors. Cai L; Chen A; Tang D Immunology; 2024 Oct; 173(2):209-226. PubMed ID: 38517066 [TBL] [Abstract][Full Text] [Related]
28. Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series. Zhou C; Jiang T; Xiao Y; Wang Q; Zeng Z; Cai P; Zhao Y; Zhao Z; Wu D; Lin H; Sun C; Zhang R; Xiao W; Gao Y Front Immunol; 2021; 12():784336. PubMed ID: 34975873 [TBL] [Abstract][Full Text] [Related]
29. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients. Wang D; Zhang H; Xiang T; Wang G Front Immunol; 2021; 12():762341. PubMed ID: 34721435 [TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y Front Immunol; 2022; 13():795972. PubMed ID: 35371084 [TBL] [Abstract][Full Text] [Related]
31. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582 [TBL] [Abstract][Full Text] [Related]
32. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Lin A; Zhang J; Luo P Front Immunol; 2020; 11():2039. PubMed ID: 32903444 [TBL] [Abstract][Full Text] [Related]
33. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Picard E; Verschoor CP; Ma GW; Pawelec G Front Immunol; 2020; 11():369. PubMed ID: 32210966 [TBL] [Abstract][Full Text] [Related]
34. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer. Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z Front Immunol; 2022; 13():1001444. PubMed ID: 36159842 [TBL] [Abstract][Full Text] [Related]
35. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer. Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X Front Immunol; 2023; 14():1044353. PubMed ID: 36776899 [TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers. Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Huyghe N; Baldin P; Van den Eynde M Gastroenterol Rep (Oxf); 2020 Feb; 8(1):11-24. PubMed ID: 32104582 [TBL] [Abstract][Full Text] [Related]
38. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy? Chen M; Liu H; Liang W; Huang P; Ye F; Cai Y; Liang Z; Xiong L; Kang L; Huang L Br J Cancer; 2024 Mar; 130(5):798-807. PubMed ID: 38218920 [TBL] [Abstract][Full Text] [Related]
39. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P Cells; 2021 Jul; 10(8):. PubMed ID: 34440647 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]